Annovis Bio (ANVS) Price & Analysis

Compare

651 Followers

ANVS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.11 - $10.54

Previous CloseN/A

Volume368.97K

Average Volume (3M)265.58K

Market Cap

$45.01M

Enterprise Value$25.15M

Total Cash (Recent Filing)$17.13B

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.77

Next Earnings

Nov 05, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding19,486,230

10 Day Avg. Volume241,540

30 Day Avg. Volume265,582

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.56

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.06

Forecast

1Y Price Target

$10.00

Price Target Upside332.90% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe company initiated its pivotal Phase 3 clinical trial for buntanetap for early Alzheimer's disease, which is seen as a significant step forward.

Intellectual PropertyAnnovis announced the completion of patent transfer to the crystalline form of buntanetap, extending the IP estate around both forms of the drug to 2046.

Regulatory AlignmentAnnovis Bio previously held an end-of-Phase 2 (EOP2) meeting with the FDA, in which the agency granted clearance to Annovis Bio to proceed with pivotal Phase 3 development of buntanetap, based on the company's Phase 2/3 data showing symptomatic improvement in patients with early Alzheimer's disease.

Bears Say

Financial ChallengesFinancing required to carry out its plans remains a key consideration, with a cash runway into 4Q25.

Market ConditionsBroad market headwinds continue in 2025 including continued challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.

Stock Price TargetThe 12-month price target is reduced to $12 from the prior $30 per share to reflect the impact of the most recent equity financing, future potential equity issuances, and the exercise of warrants.

Annovis Bio News

Annovis Bio price target lowered to $10 from $12 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Annovis Bio (ANVS) to $10 from $12 and keeps a...

4h ago

ANVS

Annovis Bio completes full patent transfer to crystal buntanetap

Annovis Bio (ANVS) announced that all Company’s patents have been successfully transferred from the original form of buntanetap...

27d ago

ANVS

Annovis Bio Reports Q2 2025 Progress and Financials

Annovis Bio Inc ( ($ANVS) ) has released its Q2 earnings. Here is a breakdown of the information...

15d ago

ANVS

Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Study Overview: Annovis Bio Inc. is...

20d ago

ANVS

Annovis Bio’s Strategic Advancements and Phase 3 Study Progress Support Buy Rating

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Annovis Bio, with...

20d ago

ANVS

Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Annovis Bio Inc. is conducting a...

1M ago

ANVS

Annovis Bio Inc. Advances Alzheimer’s Treatment with Buntanetap Study

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Study Overview: Annovis Bio Inc. is...

2M ago

ANVS

Annovis Bio’s Alzheimer’s Study: A Potential Game-Changer for Investors?

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Annovis Bio Inc. is conducting a...

2M ago

ANVS

Annovis Bio’s Promising Alzheimer’s Study: A Potential Game Changer?

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Annovis Bio Inc. is conducting a...

2M ago

ANVS

Annovis Bio rises 16.3%

Annovis Bio (ANVS) is up 16.3%, or 43c to $3.07. Published first on TheFly – the ultimate source...

2M ago

ANVS

Annovis Bio Approves Board Elections and Auditor Appointment

An update from Annovis Bio ( ($ANVS) ) is now available. On June 17, 2025, Annovis Bio, Inc....

2M ago

ANVS

Annovis Bio’s NYSE Compliance Plan Accepted

Annovis Bio ( ($ANVS) ) has issued an announcement. On June 19, 2025, Annovis Bio announced that the...

3M ago

ANVS

Annovis Bio says NYSE accepted plan to regain compliance

Annovis Bio (ANVS) announced it received notification from the New York Stock Exchange that the NYSE has accepted...

3M ago

ANVS

Annovis Bio price target lowered to $12 from $30 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Annovis Bio (ANVS) to $12 from $30 and keeps a...

3M ago

ANVS

ANVS FAQ

What was Annovis Bio Inc’s price range in the past 12 months?

Annovis Bio Inc lowest stock price was $1.11 and its highest was $10.54 in the past 12 months.

What is Annovis Bio Inc’s market cap?

Annovis Bio Inc’s market cap is $45.01M.

When is Annovis Bio Inc’s upcoming earnings report date?

Annovis Bio Inc’s upcoming earnings report date is Nov 05, 2025 which is in 63 days.

How were Annovis Bio Inc’s earnings last quarter?

Annovis Bio Inc released its earnings results on Aug 12, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.082.

Is Annovis Bio Inc overvalued?

According to Wall Street analysts Annovis Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Annovis Bio Inc pay dividends?

Annovis Bio Inc does not currently pay dividends.

What is Annovis Bio Inc’s EPS estimate?

Annovis Bio Inc’s EPS estimate is -0.29.

How many shares outstanding does Annovis Bio Inc have?

Annovis Bio Inc has 19,486,230 shares outstanding.

What happened to Annovis Bio Inc’s price movement after its last earnings report?

Annovis Bio Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went down -2.527%.

Which hedge fund is a major shareholder of Annovis Bio Inc?

Currently, no hedge funds are holding shares in ANVS

Annovis Bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-365.03%

Trailing 12-Months

Asset Growth

325.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Annovis Bio Inc

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Annovis Bio (ANVS) Earnings & Revenues

Historic Earnings Reports

ANVS Stock 12 Month Forecast

Average Price Target

$10.00

▲(332.90% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.51,3.2399999999999998,3.9699999999999998,4.699999999999999,5.43,6.16,6.89,7.619999999999999,8.35,9.08,9.809999999999999,10.54,11.27,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.51,3.086153846153846,3.6623076923076923,4.238461538461538,4.814615384615385,5.39076923076923,5.966923076923076,6.543076923076923,7.119230769230769,7.695384615384615,8.271538461538462,8.847692307692308,9.423846153846153,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.51,2.9323076923076923,3.3546153846153843,3.776923076923077,4.199230769230769,4.621538461538462,5.043846153846154,5.466153846153846,5.888461538461538,6.310769230769231,6.733076923076923,7.155384615384615,7.577692307692308,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.27,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.09,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.87,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >